论文部分内容阅读
目的对阿奇霉素联合痰热清治疗小儿肺炎支原体肺炎的临床效果进行分析探讨。方法 70例肺炎支原体肺炎患儿,随机分为研究组和对照组,各35例。两组患儿在治疗初期进行止咳、辅以吸氧以及退热化痰等辅助治疗,同时施以阿奇霉素的序贯治疗,研究组在此基础上施以痰热清辅助治疗,对比观察两组患儿的治疗效果。结果研究组总有效率为94.29%,对照组总有效率为71.43%,比较差异具有统计学意义(P<0.05)。研究组患儿在治疗后其退热化痰、止咳、住院以及肺部啰音等症状消失的时间较对照组患儿明显变短,比较差异具有统计学意义(P<0.05)。研究组不良反应发生率为14.29%(5/35),对照组为48.57%(17/35);比较差异具有统计学意义(χ~2=9.545,P<0.05)。结论阿奇霉素联合痰热清的治疗方法对于治疗小儿肺炎支原体肺炎具有良好的临床效果,安全性好,治疗后患儿的临床及身体相关的体征消失较快,发热时间大大缩短,因而治疗效果显著,值得在临床上进行推广应用。
Objective To analyze the clinical effect of azithromycin combined with Tanreqing on children with Mycoplasma pneumoniae pneumonia. Methods Seventy patients with Mycoplasma pneumoniae pneumonia were randomly divided into study group and control group, with 35 cases in each group. Two groups of children in the early treatment of cough, supplemented by oxygen and antipyretic sputum and other adjuvant therapy, at the same time with azithromycin sequential treatment, the study group on the basis of the application of Tanreqing adjuvant therapy, compared two groups Children’s treatment. Results The total effective rate was 94.29% in the study group and 71.43% in the control group, the difference was statistically significant (P <0.05). After treatment, the children in the study group had significantly shorter disappearance of symptoms such as fever, phlegm, cough, hospitalization and pulmonary rales compared with those in the control group. The difference was statistically significant (P <0.05). The incidence of adverse reactions was 14.29% (5/35) in the study group and 48.57% (17/35) in the control group. The difference was statistically significant (χ ~ 2 = 9.545, P <0.05). Conclusion The treatment of azithromycin combined with Tanreqing has a good clinical effect for the treatment of children with Mycoplasma pneumoniae pneumonia and has good safety. After treatment, the clinically and physically related signs disappear rapidly and the fever time is greatly shortened, thus the treatment effect is remarkable, It is worth to promote the clinical application.